Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Gibson highlighted, "Recursion has a tremendous amount of potential catalysts coming in the next 18 months," referencing the pipeline, partnerships, and platform advancements. He reported, "a pro ...

Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...

Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

One of the new mechanics added in Marvel Rivals Season 1 was Recursive Destruction, and fans have been quite curious to know what it is all about. Marvel Rivals offers a variety of different maps that ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

It may sound counterintuitive to use AI to prepare for AI, but this recursive strategy is what enables scalable ... like a ...